SCHEMBL1472478

SCHEMBL1472478

CC(O)c1cccc(-c2ccc3nc(-c4cccc(F)c4)cn3c2)c1

nearest known ligand 0.73

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
NR4A2 P43354 5/20 0.73
ALDH1A3 P47895 11/20 0.54
ALDH1A1 P00352 3/20 0.47
ALDH1A2 O94788 1/20 0.47
EGLN1 Q9GZT9 1/20 0.47
KCNH2 Q12809 2/20 0.47
SLC2A1 P11166 1/20 0.46
CYP2C9 P11712 1/20 0.46
HPGDS O60760 1/20 0.44
NPC1 O15118 1/20 0.43
POLB P06746 1/20 0.43
PKM P14618 1/20 0.43
CASP6 P55212 1/20 0.43
GFER P55789 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
CDK8 P49336 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1472462 0.92 NR4A2 (0.79) NR4A2ALDH1A3ALDH1A1ALDH1A2KCNH2
SCHEMBL1472600 0.90 NR4A2 (0.76) NR4A2ALDH1A3ALDH1A1ALDH1A2KCNH2
SCHEMBL1472718 0.87 NR4A2 (0.65) NR4A2ALDH1A3ALDH1A1ALDH1A2EGLN1
SCHEMBL1472616 0.86 NR4A2 (0.85) NR4A2ALDH1A3ALDH1A1ALDH1A2EGLN1
SCHEMBL1472436 0.85 NR4A2 (1.00) NR4A2ALDH1A3ALDH1A1ALDH1A2KCNH2
SCHEMBL1473059 0.80 NR4A2 (0.74) NR4A2ALDH1A3ALDH1A1ALDH1A2KCNH2
SCHEMBL1474684 0.79 NR4A2 (0.72) NR4A2ALDH1A3ALDH1A1ALDH1A2EGLN1
SCHEMBL21708004 0.77 NPC1 (0.65) ALDH1A3ALDH1A1SLC2A1HPGDSNPC1
SCHEMBL2430531 0.75 APP (0.62) NR4A2ALDH1A3ALDH1A1ALDH1A2SLC2A1
SCHEMBL2064834 0.75 ALDH1A3 (0.62) NR4A2ALDH1A3ALDH1A1EGLN1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7915284-B2 2-aryl-6-phenylimidazo[1,2-a]pyridine derivatives, preparation thereof and therapeutic use thereof SANOFI-AVENTIS (FR) 2011-03-29 US claimed
EP-2069342-B1 2-ARYL-6-PHENYLIMIDAZO[1,2-A]PYRIDINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI AVENTIS (FR) 2010-05-12 EP claimed
US-20090253735-A1 2-ARYL-6-PHENYLIMIDAZO[1,2-a]PYRIDINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2009-10-08 US claimed
US-7915284-B2 2-aryl-6-phenylimidazo[1,2-a]pyridine derivatives, preparation thereof and therapeutic use thereof SANOFI-AVENTIS (FR) 2011-03-29 US disclosed
EP-2069342-B1 2-ARYL-6-PHENYLIMIDAZO[1,2-A]PYRIDINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI AVENTIS (FR) 2010-05-12 EP disclosed
US-20090253735-A1 2-ARYL-6-PHENYLIMIDAZO[1,2-a]PYRIDINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2009-10-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090253735-A1 2-ARYL-6-PHENYLIMIDAZO[1,2-a]PYRIDINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF NCOR1, NR4A2, NR4A3 NR4A2 2/4885ALDH1A3 1043/4885ALDH1A1 1788/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.